Cargando…
Janus kinase inhibitor, tofacitinib, in refractory juvenile dermatomyositis: a retrospective multi-central study in China
OBJECTIVES: Juvenile dermatomyositis (JDM) is a chronic autoimmune disease. Some patients remain in an active state even though they were administrated with a combination of corticosteroid and methotrexate. Existing research has suggested that interferon and Janus kinase played an important role in...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583374/ https://www.ncbi.nlm.nih.gov/pubmed/37853451 http://dx.doi.org/10.1186/s13075-023-03170-z |
_version_ | 1785122537503457280 |
---|---|
author | Zhang, Junmei Sun, Li Shi, XinWei Li, Shipeng Liu, Cuihua Li, Xiaoqing Lu, Meiping Deng, Jianghong Tan, Xiaohua Guan, Wanzhen Li, Guomin Wen, Xinran Liu, Ping Li, Caifeng |
author_facet | Zhang, Junmei Sun, Li Shi, XinWei Li, Shipeng Liu, Cuihua Li, Xiaoqing Lu, Meiping Deng, Jianghong Tan, Xiaohua Guan, Wanzhen Li, Guomin Wen, Xinran Liu, Ping Li, Caifeng |
author_sort | Zhang, Junmei |
collection | PubMed |
description | OBJECTIVES: Juvenile dermatomyositis (JDM) is a chronic autoimmune disease. Some patients remain in an active state even though they were administrated with a combination of corticosteroid and methotrexate. Existing research has suggested that interferon and Janus kinase played an important role in pathogenesis. Existing research has suggested the efficacy of JAK inhibitors (JAKi). Our retrospective study aimed to investigate the efficacy of tofacitinib in refractory JDM patients. METHODS: A total of eighty-eight patients in China who had been diagnosed with JDM and subjected to tofacitinib therapy for over 3 months were retrospectively analyzed. Skin and muscle manifestations were assessed using the Cutaneous Assessment Tool-binary method (CAT-BM), Childhood Myositis Assessment Scale (CMAS), and kinase. Pulmonary function was assessed using a high-resolution CT (computerized tomography) scan and pulmonary symptoms. All patients were subjected to regular follow-up, and core measures were assessed every 3 months after initiation. Furthermore, the data were analyzed using the Wilcoxon single test, Mann–Whitney U test, and chi-square test. RESULTS: Compared with the baseline data, skin and muscle manifestations were found significantly improved during the respective follow-up visit. At the most recent follow-up, nearly 50% of patients achieved a clinical complete response and six patients received tofacitinib monotherapy. Sixty percent of patients suffering from interstitial lung disease well recovered on high-resolution CT. Seventy-five percent of patients showed a reduction in the size or number of calcinosis, and 25% of patients showed completely resolved calcinosis. CONCLUSION: In this study, the result suggested that tofacitinib therapy exerted a certain effect on skin manifestations, muscle manifestations, interstitial lung disease (ILD), calcinosis, as well as downgrade of medication. In-depth research should be conducted to focus on the correlation between the pathogenesis of JDM and JAKi. |
format | Online Article Text |
id | pubmed-10583374 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-105833742023-10-19 Janus kinase inhibitor, tofacitinib, in refractory juvenile dermatomyositis: a retrospective multi-central study in China Zhang, Junmei Sun, Li Shi, XinWei Li, Shipeng Liu, Cuihua Li, Xiaoqing Lu, Meiping Deng, Jianghong Tan, Xiaohua Guan, Wanzhen Li, Guomin Wen, Xinran Liu, Ping Li, Caifeng Arthritis Res Ther Research OBJECTIVES: Juvenile dermatomyositis (JDM) is a chronic autoimmune disease. Some patients remain in an active state even though they were administrated with a combination of corticosteroid and methotrexate. Existing research has suggested that interferon and Janus kinase played an important role in pathogenesis. Existing research has suggested the efficacy of JAK inhibitors (JAKi). Our retrospective study aimed to investigate the efficacy of tofacitinib in refractory JDM patients. METHODS: A total of eighty-eight patients in China who had been diagnosed with JDM and subjected to tofacitinib therapy for over 3 months were retrospectively analyzed. Skin and muscle manifestations were assessed using the Cutaneous Assessment Tool-binary method (CAT-BM), Childhood Myositis Assessment Scale (CMAS), and kinase. Pulmonary function was assessed using a high-resolution CT (computerized tomography) scan and pulmonary symptoms. All patients were subjected to regular follow-up, and core measures were assessed every 3 months after initiation. Furthermore, the data were analyzed using the Wilcoxon single test, Mann–Whitney U test, and chi-square test. RESULTS: Compared with the baseline data, skin and muscle manifestations were found significantly improved during the respective follow-up visit. At the most recent follow-up, nearly 50% of patients achieved a clinical complete response and six patients received tofacitinib monotherapy. Sixty percent of patients suffering from interstitial lung disease well recovered on high-resolution CT. Seventy-five percent of patients showed a reduction in the size or number of calcinosis, and 25% of patients showed completely resolved calcinosis. CONCLUSION: In this study, the result suggested that tofacitinib therapy exerted a certain effect on skin manifestations, muscle manifestations, interstitial lung disease (ILD), calcinosis, as well as downgrade of medication. In-depth research should be conducted to focus on the correlation between the pathogenesis of JDM and JAKi. BioMed Central 2023-10-18 2023 /pmc/articles/PMC10583374/ /pubmed/37853451 http://dx.doi.org/10.1186/s13075-023-03170-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Zhang, Junmei Sun, Li Shi, XinWei Li, Shipeng Liu, Cuihua Li, Xiaoqing Lu, Meiping Deng, Jianghong Tan, Xiaohua Guan, Wanzhen Li, Guomin Wen, Xinran Liu, Ping Li, Caifeng Janus kinase inhibitor, tofacitinib, in refractory juvenile dermatomyositis: a retrospective multi-central study in China |
title | Janus kinase inhibitor, tofacitinib, in refractory juvenile dermatomyositis: a retrospective multi-central study in China |
title_full | Janus kinase inhibitor, tofacitinib, in refractory juvenile dermatomyositis: a retrospective multi-central study in China |
title_fullStr | Janus kinase inhibitor, tofacitinib, in refractory juvenile dermatomyositis: a retrospective multi-central study in China |
title_full_unstemmed | Janus kinase inhibitor, tofacitinib, in refractory juvenile dermatomyositis: a retrospective multi-central study in China |
title_short | Janus kinase inhibitor, tofacitinib, in refractory juvenile dermatomyositis: a retrospective multi-central study in China |
title_sort | janus kinase inhibitor, tofacitinib, in refractory juvenile dermatomyositis: a retrospective multi-central study in china |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583374/ https://www.ncbi.nlm.nih.gov/pubmed/37853451 http://dx.doi.org/10.1186/s13075-023-03170-z |
work_keys_str_mv | AT zhangjunmei januskinaseinhibitortofacitinibinrefractoryjuveniledermatomyositisaretrospectivemulticentralstudyinchina AT sunli januskinaseinhibitortofacitinibinrefractoryjuveniledermatomyositisaretrospectivemulticentralstudyinchina AT shixinwei januskinaseinhibitortofacitinibinrefractoryjuveniledermatomyositisaretrospectivemulticentralstudyinchina AT lishipeng januskinaseinhibitortofacitinibinrefractoryjuveniledermatomyositisaretrospectivemulticentralstudyinchina AT liucuihua januskinaseinhibitortofacitinibinrefractoryjuveniledermatomyositisaretrospectivemulticentralstudyinchina AT lixiaoqing januskinaseinhibitortofacitinibinrefractoryjuveniledermatomyositisaretrospectivemulticentralstudyinchina AT lumeiping januskinaseinhibitortofacitinibinrefractoryjuveniledermatomyositisaretrospectivemulticentralstudyinchina AT dengjianghong januskinaseinhibitortofacitinibinrefractoryjuveniledermatomyositisaretrospectivemulticentralstudyinchina AT tanxiaohua januskinaseinhibitortofacitinibinrefractoryjuveniledermatomyositisaretrospectivemulticentralstudyinchina AT guanwanzhen januskinaseinhibitortofacitinibinrefractoryjuveniledermatomyositisaretrospectivemulticentralstudyinchina AT liguomin januskinaseinhibitortofacitinibinrefractoryjuveniledermatomyositisaretrospectivemulticentralstudyinchina AT wenxinran januskinaseinhibitortofacitinibinrefractoryjuveniledermatomyositisaretrospectivemulticentralstudyinchina AT liuping januskinaseinhibitortofacitinibinrefractoryjuveniledermatomyositisaretrospectivemulticentralstudyinchina AT licaifeng januskinaseinhibitortofacitinibinrefractoryjuveniledermatomyositisaretrospectivemulticentralstudyinchina |